Skip to main content

PATOLOGIA SINAPTICA EN MODELOS DE ENFERMEDAD DE ALZHEIMER: RECEPTORES AMPA, RECEPTORES DE EFRINAS Y DINAMICA DEL CITOESQUELETO

SAF2008-02342

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2008
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

New serotonin 5-HT1A receptor agonists with neuroprotective effect against ischemic cell damage

  • Marco, Isabel
  • Valhondo Falcón, Margarita
  • Martín-Fontecha Corrales, María Del Mar
  • Vázquez Villa, María Del Henar
  • Del Rio, Joaquin
  • Planas, Anna
  • Sagredo Ezquioga, Onintza
  • Ramos Atance, José Antonio
  • Torrecillas, Iván R.
  • Pardo, Leonardo
  • Frechilla, Diana
  • Benhamú Salama, Bellinda
  • López Rodríguez, María Luz
We report the synthesis of new compounds 4–35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT1A receptor (5-HT1AR). Computational β2-based homology models of the ligand–receptor complexes were used to explain the observed structure–affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4-dihydro-2H-chromen-2-ylmethyl)amino]hexyl}tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione) has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 5.9 nM, EC50 = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats.